Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
  • Patent number: 10253330
    Abstract: Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 9, 2019
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Daniel Goldowitz, Charles de Leeuw
  • Patent number: 10227598
    Abstract: Identification of new enhancer sequence has significant utility in the plant functional genomics. The sugarcane bacilliform badnavirus (SCBV) transcriptional enhancer has been identified. This enhancer can be used to increase the rate of transcription from gene promoters and in activation tagging experiments. A ten-fold increase in transcription was observed when a 4× array of the SCBV enhancer was placed upstream of a truncated form of the maize alcohol dehydrogenase minimal promoter. Methods of using the SCBV transcriptional enhancer are described, as are chimeric transcription regulatory regions, constructs, cells, tissues, and organisms that comprise one or more copies of the enhancer.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: March 12, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: John P. Davies, Vaka S. Reddy, William M. Ainley, Mark A. Thompson
  • Patent number: 10167467
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: January 1, 2019
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9982258
    Abstract: The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double stranded RNA molecules, as well as compositions and commodity products containing or treated with such molecules.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: May 29, 2018
    Assignee: Devgen NV
    Inventors: Romaan Raemaekers, Pascale Feldmann, Geert Plaetinck, Irene Nooren, Frederic Pecqueur, Laurent Kubler, Nicole Damme, Lies Degrave, Isabel Remory, Thierry Bogaert
  • Patent number: 9970004
    Abstract: Subjects of the invention are: nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG-type repeats. Solution relates to the new concept of treating hereditary human neurological diseases caused by expansion of CAG-type trinucleotide repeats using RNA interference technology.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: May 15, 2018
    Assignee: INSTYTUT CHEMII BIOORGANICZNEJ PAN
    Inventors: Wlodzimierz Krzyzosiak, Marta Olejniczak, Paulina Galka-Marciniak, Agnieszka Fiszer
  • Patent number: 9957555
    Abstract: The invention relates to a method for the detection of the occurrence of initiation of replication events in genomic DNA in a eukaryotic cell, involving contacting said eukaryotic cell comprising said genomic DNA with a first nucleotide probe, under conditions enabling in situ hybridization of said first nucleotide probe with a target region in the DNA genome, wherein said target region comprises a nucleic acid sequence which has no identified corresponding annealing RNA in a metabolically active cell and therefore remains RNA-free during transcription and replication of said DNA genome and detecting said first nucleotide probe hybridized to said DNA. Further detection of at least one RNA molecule can be achieved.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: May 1, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Laurent Arnaud Chatre, Miria Ricchetti
  • Patent number: 9951347
    Abstract: The invention provides novel recombinant DNA molecules and constructs useful for modulating gene expression in plants, plant cells, seeds, and progeny plants. Plant regulatory elements comprising sequences from the Ubq10 gene of C. lacryma-jobi, as well as variants and fragments thereof having gene regulatory activity, are provided. The invention also provides transgenic plants, plant cells, plant parts, seeds, and progeny plants comprising the recombinant DNA molecules of the invention, along with methods of their use.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: April 24, 2018
    Assignee: Monsanto Technology LLC
    Inventor: Stanislaw Flasinski
  • Patent number: 9920318
    Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: March 20, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Scott D. Estes, Weiqun Zhang
  • Patent number: 9879297
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: January 30, 2018
    Assignee: SELEXIS SA
    Inventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Patent number: 9850269
    Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: December 26, 2017
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Anusha Dias, Shrirang Karve, Michael Heartlein
  • Patent number: 9803212
    Abstract: The present invention pertains to a method of expressing a protein of interest, preferably a heterologous protein, in preferably a plant. In a preferred embodiment said plant is a doubled haploid homozygous transgenic Nicotiana tabacum plant silenced for Ntp303. Furthermore, the invention relates to said plant with or without nucleic acid constructs according to the invention. Propagation, harvest and tissue material of said transgenic Nicotiana tabacum plant is also a part of the invention.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: October 31, 2017
    Assignee: R1 B3 Holding B.V.
    Inventors: Marinus Maria Antonius Van Herpen, Jozef Maurinus Raymond Hulzink, Anton Felix Croes
  • Patent number: 9765345
    Abstract: The present invention aims to provide a promoter showing high expression activity in microorganisms belonging to the genus Mortierella. The present invention provides a polynucleotide which contains a nucleotide sequence selected from SEQ ID NOs: 1 to 28, or a variant thereof, as well as a non-human transformant containing such a polynucleotide.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: September 19, 2017
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Misa Ochiai, Jun Ogawa, Eiji Sakuradani, Akinori Ando
  • Patent number: 9631202
    Abstract: The invention provides specific transgenic soybean plants, plant material and seeds, characterized in that these products harbor a specific herbicide tolerance transformation event at a specific location in the soybean genome. Tools are also provided which allow rapid and unequivocal identification of the event in biological samples.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: April 25, 2017
    Assignees: M.S. TECHNOLOGIES LLC, BAYER CROPSCIENCE N.V.
    Inventors: Justin Thomas Mason, Leslie James Lettow, Mark Alan Eby, William H. Eby, Günter Welz, Steven Verhaeghe, Marc De Beuckeleer, Veerle Habex, Jean-Marc Ferrulo
  • Patent number: 9624492
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: April 18, 2017
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9464293
    Abstract: In some embodiments, aptamers that specifically bind pancreatic cancer cells are provided. Such aptamers may include an RNA molecule that specifically binds a pancreatic cancer cell surface protein. In certain embodiments, the RNA molecule that is used as an aptamer may include a nucleotide sequence of GAAUGCCC (SEQ ID NO: 8). In other embodiments, the RNA molecule may include a nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6. In certain embodiments, the aptamer may be conjugated to one or more therapeutic agents (e.g., an shRNA molecule, an siRNA molecule, an mRNA molecule, or an miRNA molecule), one or more diagnostic agents, or a combination thereof. The aptamers and their conjugates may be used to deliver therapeutic agents to a pancreatic cancer cell, and/or in methods for treating or diagnosing pancreatic cancer.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 11, 2016
    Assignee: CITY OF HOPE
    Inventors: John J. Rossi, Sorah Yoon
  • Patent number: 9447419
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 20, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • Patent number: 9428815
    Abstract: The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: August 30, 2016
    Assignee: Emory University
    Inventor: Raymond F. Schinazi
  • Patent number: 9410159
    Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: August 9, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
  • Patent number: 9403887
    Abstract: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 2, 2016
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eyal Breitbart, Livnat Bangio, Reshef Tal
  • Patent number: 9334539
    Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: May 10, 2016
    Assignees: The Hospital for Sick Children, McGill University, The Regents of the University of California, U.S. Department of Veterans Affairs
    Inventors: Stephen W. Scherer, Berge A. Minassian, Antonio Delgado-Escueta, Guy Rouleau
  • Patent number: 9333218
    Abstract: The disclosure relates to microRNAs (miRNAs) for the prophylaxis and/or treatment of neoplasia. The disclosure relates in particular to sequence corresponding to miR2 and the miR-548 family, including precursors, mature forms, fragments, and combinations thereof for the prophylaxis and/or treatment of neoplasias, particularly lung, stomach, and cervical cancer, alone or in combination with additional cancer treatments and therapeutics.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: May 10, 2016
    Assignee: Emory University
    Inventors: Ya Wang, Baocheng Hu, Walter J. Curran
  • Patent number: 9322028
    Abstract: Non-naturally occurring DNA promoters, include MSGT-PFlt, PFlt-UAS-2X and FSgt-PFlt. The MSGT-PFlt was developed and has expression shown to be equivalent to that of CaMV35S promoter. DNA promoters PFlt-UAS-2X and FSgt-PFlt were developed and tested in transient and transgenic system and found to be stronger than the CaMV35S promoter.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: April 26, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Indu Maiti, Nrisingha Dey
  • Patent number: 9303266
    Abstract: The invention provides novel recombinant DNA molecules and constructs useful for modulating gene expression in plants, plant cells, seeds, and progeny plants. The invention also provides transgenic plants, plant cells, plant parts, seeds, and progeny plants comprising the recombinant DNA molecules of the invention, along with methods of their use.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: April 5, 2016
    Assignee: Monsanto Technology LLC
    Inventor: Stanislaw Flasinski
  • Patent number: 9297018
    Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 29, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
  • Patent number: 9297019
    Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 29, 2016
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
  • Patent number: 9198927
    Abstract: The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing (RNAi), wherein the antiviral methods and compositions preferentially target opposite strand replication intermediates of single-stranded RNA viruses.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: December 1, 2015
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Daniel E. McCallus, Catherine Pachuk, Baohua Gu
  • Patent number: 9187757
    Abstract: The subject invention concerns materials and methods for modulating lignin biosynthesis in sugarcane plants. In one embodiment, lignin biosynthesis is down-regulated. Genes and the proteins encoded thereby that can be targeted for achieving down-regulation of lignin in sugarcane include, for example, 4-coumarate-CoA ligase (4CL). In one embodiment, the 4CL gene is 4CL-M, 4CL-N, or 4CL-L. The subject invention also concerns a sugarcane plant, specific plant tissue, and plant cells having modulated (e.g., down-regulated) lignin biosynthesis. The subject invention also concerns methods for producing a sugarcane plant having modulated (e.g., decreased or down-regulated) biosynthesis of lignin.
    Type: Grant
    Filed: June 5, 2010
    Date of Patent: November 17, 2015
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Fredy Altpeter, Walid Mohamed Fouad, Maria Gallo, Je Hyeong Jung, Yuan Xiong
  • Patent number: 9163250
    Abstract: The invention found that partial deletion of the glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter can enhance gene expression (even heterologous gene expression) in basidiomycetous fungi. With the discovery of these gpd promoters, an expression system can be constructed for the expression of a heterologous gene in mushroom. Accordingly, the invention provides a truncated glyceraldehyde-3-phosphate dehydrogenase promoter and a construct comprising the promoter of the invention operably linked to a heterologous transcribable polynucleotide molecule and a mushroom comprising the construct.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: October 20, 2015
    Assignee: MYCOMAGIC BIOTECHNOLOGY CO., LTD.
    Inventor: Ying-Tzu Lyu
  • Patent number: 9096878
    Abstract: The present inventors conducted dedicated studies and successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired dihydrofolate reductase gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: August 4, 2015
    Assignees: National University Corporation Hokkaido University, Fuso Pharmaceutical Industries, Ltd.
    Inventors: Hiroshi Tahara, Yusuke Suzuki, Keiichi Yamamoto, Yuzuru Kitahara, Yasuhiko Suzuki
  • Patent number: 9096637
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 4, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
  • Patent number: 9056886
    Abstract: The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: June 16, 2015
    Assignee: APTABIO THERAPEUTICS INC.
    Inventors: Soo Jin Lee, Sung Hwan Moon
  • Publication number: 20150147782
    Abstract: The present invention relates to a light-inducible promoter and a gene expression system containing the same, and provides: a light-inducible promoter comprising a nucleotide sequence represented by SEQ ID NO: 12; and a method for producing heterologous proteins using the same. Since the light-inducible promoter of the present invention induces the expression of a gene by the irradiation of light and regulates an expression amount of the gene according to an intensity of light, it is possible to conveniently regulate the expression of the gene without straining the growth or metabolic process of an organism. In addition, the present invention can be applied to various types of organisms, and thus has a wide range of application.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 28, 2015
    Inventors: Eon Seon Jin, Jae Hyeok Lee, Seung Hye Park, Kwang Ryul Baek
  • Patent number: 9040776
    Abstract: The invention relates to genes coding for TCP family transcription factors and having a biological role in the development of axillary buds and branch growth. Furthermore, the invention relates to the promoters of the transcription of said genes, to the genetic constructs containing same and to the uses thereof, including the use of agents that modulate the expression of these genes in order to modify plant architecture.
    Type: Grant
    Filed: November 27, 2009
    Date of Patent: May 26, 2015
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Mar Martín Trillo, María Luisa Rodríguez Buey, Pilar Cubas Domínguez
  • Publication number: 20150143582
    Abstract: The invention relates to a pathogen-inducible synthetic promoter which is suitable for regulating the transcription of a nucleic acid, and includes a minimal promoter, characterized in that the minimal promoter includes a sequence motif a) dbrmwa or b) twcccmt which is disposed downstream from a TATA region and in front of a transcription starting point which is located on the minimal promoter and at which transcription of the nucleic acid to be regulated starts.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventor: Klaus Schmidt
  • Publication number: 20150135368
    Abstract: The invention relates to promoters for stress-induced expression in plants as well as to methods for rendering any given promoter into a stress-inducible promoter. The invention further relates to promoter sequences produced with such methods and their use for stress-induced gene expression.
    Type: Application
    Filed: February 28, 2013
    Publication date: May 14, 2015
    Applicant: BASFPlant Scence Company GmbH
    Inventors: Anke Eisenmann, Lorenz Bülow, Yves Hatzfeld, Zhongyi Zhou
  • Publication number: 20150133528
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 14, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20150135362
    Abstract: The invention provides DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. Transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides are also provided, as are methods of their use.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 14, 2015
    Applicant: MONSANTO TECHNOLOGY LLC
    Inventors: Stanislaw Flasinski, Barrett C. Foat, Mohammed Oufattole, Randall W. Shultz, Xiaoping Wei, Wei Wu, Shiaw-Pyng Yang
  • Patent number: 9029339
    Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: May 12, 2015
    Assignee: CoDa Therapeutics, Inc.
    Inventors: David Laurence Becker, Colin Richard Green, Bradford J. Duft
  • Patent number: 9029523
    Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait. One of ordinary skill in the art, having this data, can obtain cloned DNA fragments, synthetic DNA fragments or polypeptides constituting desired sequences by recombinant methodology known in the art or described herein.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: May 12, 2015
    Assignee: Ceres, Inc.
    Inventors: Nickolai Alexandrov, Nestor Apuya, Vyacheslav Brover, Jean-Baptiste Dumas, Yiwen Fang, Ken Feldmann, Diane Jofuku, Edward A. Kiegle, Bill Kimmerly, Shing Kwok, Peter Mascia, Jack Okamuro, Roger Pennell, Richard Schneeberger, Tatiana Tatarinova, Wayne Volkmuth
  • Publication number: 20150128302
    Abstract: The present invention provides compositions and methods for regulating expression of heterologous nucleotide sequences in a plant. Compositions are novel nucleotide sequences for a constitutive regulatory element isolated from sorghum. A method for expressing a heterologous nucleotide sequence in a plant using the regulatory sequences disclosed herein is provided. The method comprises transforming a plant cell to comprise a heterologous nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed plant from the transformed plant cell.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 7, 2015
    Inventor: Shane Abbitt
  • Publication number: 20150126438
    Abstract: The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by detecting the levels of a novel isoform of ChREBP, termed ChREBP ?. The invention also provides nucleic acids, proteins, reporter constructs based on ChREBP ? and methods of identifying one or more agents that modulate the expression of a ChREBP ? target gene.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 7, 2015
    Inventors: Mark A. Herman, Barbara B. Kahn
  • Patent number: 9024005
    Abstract: The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 5, 2015
    Assignee: Procarta Biosystems Ltd
    Inventor: Michael McArthur
  • Publication number: 20150121568
    Abstract: Compositions and methods for regulating expression of heterologous nucleotide sequences in a plant are provided. Compositions include nucleotide sequences for an Arabidopsis thaliana (AT SVL3) promoter. Also provided is a method for expressing a heterologous nucleotide sequence in a plant using a promoter sequence disclosed herein.
    Type: Application
    Filed: January 15, 2015
    Publication date: April 30, 2015
    Inventors: Mark Alan Chamberlin, Shai Joshua Lawitt
  • Patent number: 9018002
    Abstract: A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 28, 2015
    Assignee: State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon State University
    Inventors: James C. Carrington, Edwards Allen
  • Patent number: 9018365
    Abstract: The invention provides methods and compositions for attaching oligonucleotide tags to polynucleotides for the purpose of carrying out analytical assays in parallel and for decoding the oligonucleotide tags of polynucleotides selected in such assays. Words, or subunits, of oligonucleotide tags index submixtures in successively more complex sets of submixtures (referred to herein as “tiers” of submixtures) that a polynucleotide goes through while successive words are added to a growing tag. By identifying each word of an oligonucleotide tag, a series of submixtures is identified including the first submixture that contains only a single polynucleotide, thereby providing the identity of the selected polynucleotide. The analysis of the words of an oligonucleotide tag can be carried out in parallel, e.g.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: April 28, 2015
    Assignee: Population Genetics Technologies Ltd
    Inventor: Sydney Brenner
  • Patent number: 9017938
    Abstract: This invention concerns the use of MicroRNA-199b-5p in medical and diagnostic fields. Particularly, this invention concerns the use of the miR199b-5p in the anti-cancer therapy and as a histophatological and metastasis marker.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: April 28, 2015
    Assignee: Advanced Accelerator Applications
    Inventor: Massimo Zollo
  • Patent number: 9018182
    Abstract: Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: April 28, 2015
    Assignees: Green Cross Corporation, Mogam Biotechnology Research Institute, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Daekyung Koh, Seongtae Yun, Kyuhyun Lee, Hong-Kyu Lee, Mihee Hwang, Chae-Ok Yun, Eui-Cheol Jo
  • Publication number: 20150111957
    Abstract: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.
    Type: Application
    Filed: September 24, 2014
    Publication date: April 23, 2015
    Inventors: Eyal Breitbart, Livnat Bangio, Reshef Tal
  • Publication number: 20150111954
    Abstract: The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.
    Type: Application
    Filed: November 9, 2012
    Publication date: April 23, 2015
    Inventors: Piotr Sliz, Yunsun NAM
  • Patent number: 9012720
    Abstract: A polynucleotide isolated from soybean plants capable of initiating transcription and with sequence identity to SEQ ID No. 1 is provided. In some aspects, the polynucleotide has sequence identity to SEQ ID No. 1 of at least 40%, is the reverse complement or the reverse of such sequences. In some aspects, the polynucleotide is linked to expression enhancers or sequences of interest. In some embodiments, a recombinant vector comprises the polynucleotide. In some aspects, the recombinant vector comprises enhancers, termination sequences, or sequences of interest. In some embodiments a transformed cell, plant, plant part, or propagulum comprise the polynucleotide.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: April 21, 2015
    Assignee: Empresa Brasileira de Pesquisa Agropecuaria
    Inventors: Maria Fatima Grossi de Sa, Luciane Mourao Guimaraes, Joao Aguiar Nogueira Batista, Antonio Americo Barbosa Viana, Rodrigo da Rocha Fragoso, Maria Cristina Mattar da Silva